Pharmacokinetic study of enzalutamide and cabazitaxel combination therapy in metastatic castrate-resistant prostate cancer (mCRPC) patients
Phase of Trial: Phase I
Latest Information Update: 03 May 2017
At a glance
- Drugs Enzalutamide (Primary) ; Cabazitaxel
- Indications Prostate cancer
- Focus Pharmacokinetics
- Acronyms Cabenza
- 29 Apr 2017 Status changed from active, no longer recruiting to completed.
- 18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium
- 16 Oct 2016 Status changed from recruiting to active, no longer recruiting.